MS

Treatment tested

• Methylphenidate

  Dopamine transporter inhibitor|Norepinephrine transporter inhibitor

Placebo or sham

• Maltodextrin

Other measures (1)

Inclusion Criteria: * Diagnosis of multiple sclerosis according to McDonalds criteria. * Age > 18 years * Fatigue as measured by Fatigue Severity Scale * Signed informed consent Exclusion Criteria: * Known allergy or hypersensitivity to Methylphenidate or any of its ingredients * Marked anxiety, tension and agitation * Patients with glaucoma or hyperthyroidism * Patients with motor-tics, a family history or diagnosis of Tourette´s syndrome * Treatment with monoamine oxidase inhibitors, also within a minimum of 14 days following discontinuation (hypertensive crisis may result). * Phaeochromocytoma * Pre-existing cardiovascular disorders including severe hypertension, angina, arterial occlusive disorder, heart failure, haemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, potentially life-threatening arrhythmias and channelopathies. * History of drug dependence or alcoholism * History of seizures * Pregnant women or females of childbearing potential who want to become pregnant within the study period. * Severe psychiatric disorders * Change of any medication treatment \<8 weeks before starting the study * Participation in any other clinical trial at the same time

Fatigue is a common symptom in multiple sclerosis (MS) that is characterized by physical and/or mental exhaustion. Fatigue is difficult to treat and treatment efficacy of available therapy is limited. The goal of this study is to determine whether MS-associated fatigue improves after 6 weeks of methylphenidate therapy. Treatment efficacy will be measured by a questionnaire called "Fatigue Severity Scale" (FSS).